Login to Your Account



Much-need holiday cheer for Ariad; FDA clears Iclusig’s return

By Jennifer Boggs
Managing Editor

Friday, December 20, 2013
Ariad Pharmaceuticals Inc. got a nice holiday gift from the FDA allowing for immediate resumption of sales of leukemia drug Iclusig (ponatinib), two months after it was suspended from the market, and pushing shares of the troubled biotech up 16.5 percent Friday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription